Viridian Shares Jump After Elegrobart Phase 3 REVEAL-2 Shows Strong Results
Viridian Therapeutics stock climbed 40% on Tuesday after the company reported positive topline results from the Phase 3 REVEAL-2 study of elegrobart in chronic thyroid eye disease. Both dosing regimens tested produced statistically significant proptosis responder rates versus placebo at week 24. The therapy was generally well tolerated, and Viridia…